Comparative study reveals dosing challenges for ceftazidime and avibactam in critically ill children, highlighting need for drug monitoring.
Ceftazidime–avibactam is a novel cephalosporin/beta‐lactamase inhibitor combination developed to address increasing antimicrobial resistance. This report presents a comparative study of the pharmacokinetics of ceftazidime and avibactam, utilizing in vitro data derived from two experiments with continuous venovenous hemodiafiltration (CVVHDF) simulation and a comparison with a previously published in vivo case report. The results highlight the importance of therapeutic drug monitoring and the need for higher dosing or continuous infusion of ceftazidime–avibactam in critically ill children under crontinuous renal replacement therapy (CRRT).
No takes yet. Share an insight, caveat, or question.
Thy et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: